Defence Therapeutics - President & CEO, Sébastien Plouffe
President & CEO, Sébastien Plouffe
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Defence Therapeutics (DTC) signed an agreement with Orano Support to develop an advanced cancer-treating radiation substance
  • The idea is to combine iDTC’s Accum technology with certain elements like antibodies to help better target and destroy cancer cells
  • DTC is responsible for developing the first radiation carrier compound therapy with its existing technology and Orano’s radiochemistry knowledge
  • Defence Therapeutics (DTC) is up 4.40 per cent, trading at $3.80 per share as of 11:53 a.m. ET

Defence Therapeutics (DTC) has signed an agreement with nuclear energy group, Orano Support, to develop an advanced cancer-treating radiation substance.

DTC stated the proposed radiation substance will use its intracellular targeting technology to support radiotherapies. Its concept is to combine its Accum technology with certain elements like antibodies to help better target and destroy cancer cells.

The Accum platform has been developed and tested in animals to enhance intranuclear drug delivery on multiple US FDA-approved antibody conjugates or new conjugates under development.

“We have a long-standing knowledge and experience working and developing our Accum platform technology, including in the antibody-conjugate therapeutics field, and we definitely believe that Orano, with its international expertise, represents a strong collaborator for the development of the next generation of radio-immuno-conjugates using Defence’s intracellular targeting technology to increase the efficacy in targeting tumoral cancer cells,” Sebastien Plouffe, President and CEO of DTC, said.

As a part of the agreement, DTC is responsible for developing the first radiation carrier compound therapy based on a specific electron emitter with its existing intracellular technology and Orano’s radiochemistry knowledge.

According to the company, existing antibody drugs for these types of treatments do exist but currently have a lower delivery rate to reach and destroy cancer cells.

Defence Therapeutics (DTC) is up 4.40 per cent, trading at $3.80 per share as of 11:53 a.m. ET.



More From The Market Herald

" Innocan Pharma (CSE:INNO) reports successful efficacy test for vaginal derma product

Innocan Pharma (INNO) has announced successful results from a controlled efficacy test of its vaginal derma product.

" @ the Bell: TSX bounces back again

Euro banking drama had a ripple effect felt on Bay Street Friday but Canada’s main stock index dodged another close in the red.
RBC

" Survey shows fraud risk a rising concern for Canadians

Latest survey by Royal Bank of Canada shows Canadians are concerned about spotting scams and that fraud risk will get worse if a recession

" A.I.S. Resources (TSXV:AIS) updates on its Argentina properties

A.I.S. Resources has provided an update to its Pocitos properties in the Salta, Argentina region.